Export financials
Burford Capital Limited (BUR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Burford Capital Limited Financial Ratios 2025-2011 | BUR
Brief overview of Burford Capital Limited's financial ratios
The review covers five available annual periods spanning 2020 to 2025.
Key multiples at the end of the period are P/E 44.48x (median 22x), EV/EBITDA 24.69x (median 16.66x), P/S 6.73x (median 6.13x). On average, this basket is 29% above its own five-year medians. The market is pricing in elevated future expectations.
At the current P/E, inverse earnings yield is 2.2%, a useful bridge between price and business earnings.
The latest available business-quality ratios are ROE 2.6%, ROA 0.9%, ROCE 9.5%. Business quality is below comfortable levels on current returns. Better margins or turnover are needed.
What the ratios show
Burford Capital Limited combines weak profitability with valuation above its historical norm, leaving limited cushion.
Annual Financial Ratios Burford Capital Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.5 | 22.0 | 4.8 | 64.1 | -80.5 | 12.2 | - | - | - | - | - | - | - | - | - | |
P/S |
6.7 | 5.9 | 2.7 | 6.1 | 10.6 | 6.3 | - | - | - | - | - | - | - | - | - |
EPS |
0.3 | 0.7 | 2.8 | 0.1 | -0.1 | 75.3 | 82.7 | 150.7 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
5.73 B | 5.67 B | 5.37 B | 3.75 B | 3.77 B | 3.22 B | 1.35 B | 690 M | 565 M | 372 M | 160 M | 151 M | 24.6 M | 12.9 M | 12.6 M |
EBITDA per Share |
1.06 | 1.78 | 3.75 | 0.91 | 0.33 | 1.11 | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
24.7 | 14.5 | 6.5 | 18.8 | 52.5 | - | - | - | - | - | - | - | - | - | - |
PEG |
0.69 | - | - | - | - | -0.57 | - | - | - | - | - | - | - | - | - |
P/B |
0.9 | 1.0 | 0.9 | 0.8 | 1.1 | 1.3 | - | - | - | - | - | - | - | - | - |
P/CF |
-95.9 | 14.9 | -10.8 | -4.2 | -4.0 | 11.6 | - | - | - | - | - | - | - | - | - |
ROE % |
2.56 | 6.05 | 26.65 | 1.75 | -1.70 | 10.10 | 13.84 | - | - | - | - | - | - | - | - |
ROA % |
0.94 | 2.37 | 10.46 | 0.71 | -0.77 | 5.51 | 6.98 | 13.69 | - | - | - | - | - | - | - |
ROCE % |
9.48 | 16.14 | 35.61 | 11.19 | 4.04 | 14.24 | 15.25 | - | - | - | - | - | - | - | - |
Current Ratio |
1.9 | 2.1 | 2.2 | 2.3 | 2.3 | 2.1 | 2.0 | 2.4 | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Burford Capital Limited
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.11 | 0.01 | -7.46 | -0.17000000000000004 | -0.09 | 0.4 | 0.14 | - | 2.79 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.45 | 0.29 | -7.18 | -0.19 | 0.11 | 0.65 | 0.35 | - | 3.75 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-106.56 | -109.47 | -106.86 | 2.20 | 30.44 | 3.26 | 1.17 | - | 26.65 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-37.96 | -39.08 | -37.64 | 1.21 | 12.41 | 1.66 | 0.60 | - | 10.46 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-93.36 | -99.06 | -98.96 | 7.24 | 43.25 | 4.41 | 2.46 | - | 35.61 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.6 | 1.5 | 1.6 | 1.9 | 1.9 | 2.0 | 2.0 | 2.1 | 2.2 | 2.3 | - | - | - | 2.3 | - | - | - | 2.6 | - | - | - | 2.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Burford Capital Limited, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Cytokinetics, Incorporated
CYTK
|
$ 50.7 | -1.48 % | $ 6.09 M | ||
|
DBV Technologies S.A.
DBVT
|
$ 9.03 | -4.14 % | $ 1.26 B | ||
|
Precision BioSciences
DTIL
|
$ 7.37 | 6.66 % | $ 94.5 M | ||
|
Exelixis
EXEL
|
$ 64.59 | -1.88 % | $ 17.5 B | ||
|
Fennec Pharmaceuticals
FENC
|
$ 13.09 | -2.68 % | $ 374 M | ||
|
Cardiff Oncology
CRDF
|
$ 0.85 | -4.67 % | $ 56.8 M | ||
|
BioNTech SE
BNTX
|
$ 80.87 | -0.63 % | $ 19.5 B | ||
|
Alkermes plc
ALKS
|
$ 44.89 | -2.79 % | $ 7.39 B | ||
|
ANI Pharmaceuticals
ANIP
|
$ 68.6 | -0.77 % | $ 1.38 B | ||
|
AIM ImmunoTech
AIM
|
$ 0.11 | -7.75 % | $ 178 K | ||
|
AC Immune SA
ACIU
|
$ 1.98 | -7.28 % | $ 199 M | ||
|
Atara Biotherapeutics
ATRA
|
$ 6.51 | 2.6 % | $ 81.7 M | ||
|
Allogene Therapeutics
ALLO
|
$ 0.63 | -5.62 % | $ 139 M | ||
|
Altimmune
ALT
|
$ 1.33 | -6.03 % | $ 117 M | ||
|
AnaptysBio
ANAB
|
$ 46.65 | -1.58 % | $ 1.35 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | ||
|
Ascendis Pharma A/S
ASND
|
$ 252.39 | -1.39 % | $ 15.3 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
$ 7.42 | -2.37 % | $ 203 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
$ 14.7 | -1.28 % | $ 1.98 B | ||
|
Autolus Therapeutics plc
AUTL
|
$ 0.91 | -6.96 % | $ 242 M | ||
|
Atea Pharmaceuticals
AVIR
|
$ 3.97 | 0.89 % | $ 324 M | ||
|
Axsome Therapeutics
AXSM
|
$ 129.32 | -4.69 % | $ 6.43 B | ||
|
BridgeBio Pharma
BBIO
|
$ 75.96 | -2.84 % | $ 14.5 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
$ 7.23 | -1.3 % | $ 1.52 B | ||
|
Bicycle Therapeutics plc
BCYC
|
$ 2.89 | -5.25 % | $ 200 M | ||
|
Benitec Biopharma
BNTC
|
$ 7.95 | -2.4 % | $ 370 M | ||
|
DiaMedica Therapeutics
DMAC
|
$ 8.24 | 2.74 % | $ 387 M | ||
|
Insmed Incorporated
INSM
|
$ 141.06 | -2.35 % | $ 28.1 B | ||
|
Iovance Biotherapeutics
IOVA
|
$ 6.9 | -5.61 % | $ 2.47 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
$ 4.64 | 17.17 % | $ 56.6 M | ||
|
InMed Pharmaceuticals
INM
|
$ 15.56 | 13.57 % | $ 64.8 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 12.36 | -9.55 % | $ 799 M | ||
|
Immutep Limited
IMMP
|
$ 3.11 | -9.06 % | $ 4.53 B | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
$ 228.26 | -3.46 % | $ 13.9 B | ||
|
BeyondSpring
BYSI
|
$ 0.33 | -24.42 % | $ 13.6 M | ||
|
Cabaletta Bio
CABA
|
$ 0.94 | -7.24 % | $ 94.5 M | ||
|
Johnson & Johnson
JNJ
|
$ 270.2 | 1.18 % | $ 650 B | ||
|
Cue Biopharma
CUE
|
$ 4.2 | -6.67 % | $ 398 M | ||
|
C4 Therapeutics
CCCC
|
$ 2.49 | 1.84 % | $ 206 M | ||
|
Codexis
CDXS
|
$ 1.0 | -5.17 % | $ 87.1 M | ||
|
Kamada Ltd.
KMDA
|
$ 7.75 | -1.02 % | $ 447 M | ||
|
Compugen Ltd.
CGEN
|
$ 1.83 | -2.66 % | $ 171 M | ||
|
Coherus BioSciences
CHRS
|
$ 0.37 | -4.06 % | $ 43.3 M | ||
|
Armata Pharmaceuticals
ARMP
|
$ 3.06 | 2.68 % | $ 111 M | ||
|
Celldex Therapeutics
CLDX
|
$ 27.36 | -2.15 % | $ 1.82 B | ||
|
Cellectis S.A.
CLLS
|
$ 0.9 | -9.7 % | $ 90.3 M | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 0.78 | -4.87 % | $ 179 M | ||
|
Edesa Biotech
EDSA
|
$ 2.01 | -7.59 % | $ 11.4 M | ||
|
Eli Lilly and Company
LLY
|
$ 1 345.4 | -0.44 % | $ 1.21 T | ||
|
Collegium Pharmaceutical
COLL
|
$ 24.73 | -1.9 % | $ 783 M |